DGIdb - FORETINIB Drug Record

FORETINIB chembl:CHEMBL1230609 Antineoplastic

Alternate Names:

EXEL-2880
XL880
GSK-1363089G
GSK1363089G
XL-880
GSK089
GSK1363089
FORETINIB
GSK 1363089G
XL 880
chembl:CHEMBL1230609
drugbank:12307
chemidplus:849217-64-7
pubchem.compound:42642645

Drug Info:

Pharmaceutical Developer	GlaxoSmithKline
Source Reported Drug Name(s)	GSK1363089
Drug Class	MET/VEGFR Inhibitor
Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent

(8 More Sources)

Publications:

Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
Choueiri et al., 2013, Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma., J. Clin. Oncol.
Song et al., 2015, Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer., Clin. Cancer Res.
Davare et al., 2015, Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors., Proc. Natl. Acad. Sci. U.S.A.

FORETINIB PTCH1

Interaction Score: 1.64

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family MET inhibitor

Alteration PTCH1:.

PMIDs:
None found

Sources:
CGI
FORETINIB ROS1

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25688157 26372962

Sources:
CIViC
FORETINIB MET

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Approval Status Preclinical

combination therapy Foretinib + Rucaparib

Evidence Type Actionable

PMIDs:
26779812 23213094

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC GuideToPharmacology CancerCommons TTD
FORETINIB TEK

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase TIE-2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FORETINIB KDR

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD
FORETINIB MST1R

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
FORETINIB FLT1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions GuideToPharmacology
FORETINIB FLT4

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions GuideToPharmacology
FORETINIB PDGFRA

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
FORETINIB KIT

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Stem cell growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FORETINIB PDGFRB

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FORETINIB FLT3

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase receptor FLT3 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FORETINIB YES1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

CancerCommons: GSK1363089
- Version: 25-July-2013
Alternate Names:

42642645 PubChem Drug ID

Foretinib Drug Trade Name

GSK1363089 Drug Development Name

Drug Info:

Drug Class MET/VEGFR Inhibitor

Source Reported Drug Name(s) GSK1363089

Pharmaceutical Developer GlaxoSmithKline

Publications:
MyCancerGenome: FORETINIB
- Version: 20-Jun-2017
Alternate Names:

EXEL-2880 Development Name

FORETINIB Generic Name

GSK1363089 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: XL880
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:
JAX-CKB: Foretinib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.

CIViC: FORETINIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Choueiri et al., 2013, Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma., J. Clin. Oncol.

Song et al., 2015, Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer., Clin. Cancer Res.

Davare et al., 2015, Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors., Proc. Natl. Acad. Sci. U.S.A.

TTD: XL880
- Version: 2020.06.01
Alternate Names:

D0D1GF TTD Drug ID

Drug Info:

Publications:
TALC: FORETINIB
- Version: 12-May-2016
Alternate Names:

FORETINIB Drug Generic Name

FORETINIB Primary Drug Name

GSK1363089 Drug Synonym

Drug Info:

Publications:
DTC: FORETINIB
- Version: 02-September-2020
Alternate Names:

CHEMBL1230609 ChEMBL Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178102306
- Version: 29-September-2020
Alternate Names:

FORETINIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1230609
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1230609
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
CGI: Foretinib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Approval Status	Preclinical
combination therapy	Foretinib + Rucaparib
Evidence Type	Actionable

Mechanism of Interaction	Tyrosine-protein kinase TIE-2 inhibitor
Direct Interaction	yes

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Direct Interaction	yes
Mechanism of Interaction	Platelet-derived growth factor receptor inhibitor

Mechanism of Interaction	Stem cell growth factor receptor inhibitor
Direct Interaction	yes

Mechanism of Interaction	Tyrosine-protein kinase receptor FLT3 inhibitor
Direct Interaction	yes

42642645	PubChem Drug ID
Foretinib	Drug Trade Name
GSK1363089	Drug Development Name

EXEL-2880	Development Name
FORETINIB	Generic Name
GSK1363089	Development Name

FORETINIB	Drug Generic Name
FORETINIB	Primary Drug Name
GSK1363089	Drug Synonym

Drug family	MET inhibitor
Alteration	PTCH1:.

FORETINIB Drug Record

FORETINIB chembl:CHEMBL1230609 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Drug family MET inhibitor Alteration PTCH1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25688157 26372962

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Approval Status Preclinical combination therapy Foretinib + Rucaparib Evidence Type Actionable

PMIDs: 26779812 23213094

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC GuideToPharmacology CancerCommons TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase TIE-2 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Stem cell growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase receptor FLT3 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

CancerCommons: GSK1363089

Alternate Names: 42642645 PubChem Drug ID Foretinib Drug Trade Name GSK1363089 Drug Development Name

Drug Info: Drug Class MET/VEGFR Inhibitor Source Reported Drug Name(s) GSK1363089 Pharmaceutical Developer GlaxoSmithKline

Publications:

MyCancerGenome: FORETINIB

Alternate Names: EXEL-2880 Development Name FORETINIB Generic Name GSK1363089 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: XL880

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class small molecule FDA Approval not approved

Publications:

JAX-CKB: Foretinib

Alternate Names:

Drug Info:

Publications: Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.

CIViC: FORETINIB

Alternate Names:

Drug Info:

TTD: XL880

Alternate Names: D0D1GF TTD Drug ID

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family MET inhibitor

Alteration PTCH1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

PMIDs:
25688157 26372962

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Approval Status Preclinical

combination therapy Foretinib + Rucaparib

Evidence Type Actionable

PMIDs:
26779812 23213094

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC GuideToPharmacology CancerCommons TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase TIE-2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Stem cell growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase receptor FLT3 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

42642645 PubChem Drug ID

Foretinib Drug Trade Name

GSK1363089 Drug Development Name

Drug Info:

Drug Class MET/VEGFR Inhibitor

Source Reported Drug Name(s) GSK1363089

Pharmaceutical Developer GlaxoSmithKline

Alternate Names:

EXEL-2880 Development Name

FORETINIB Generic Name

GSK1363089 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.

Alternate Names:

D0D1GF TTD Drug ID

Alternate Names:

FORETINIB Drug Generic Name

FORETINIB Primary Drug Name

GSK1363089 Drug Synonym

Alternate Names:

CHEMBL1230609 ChEMBL Drug ID

Alternate Names:

FORETINIB GuideToPharmacology Ligand Name